Preclinical Assessment of Atorvastatin for Treatment of Endocardial Fibroelastosis

Summary: Endocardial fibroelastosis is a condition caused by the fibrogenic activation of endothelial cells via endothelial-to-mesenchymal transition of the endocardium, which is regulated by the transforming growth factor-β pathway. Atorvastatin, a statin, can protect the vascular endothelium by up...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Daniel Diaz-Gil, MD, Gregor Gierlinger, MD, Natalia Silva-Gomez, Cand Med, Lavinia Rech, MD, PhD, Jesus Ortiz-Urbina, MD, Kerstin Saraci, Cand Med, Sophia Koutsogiannaki, PhD, Cordula M. Wolf, MD, Rainer G. Kozlik-Feldmann, MD, Rudolf Mair, MD, Juan M. Melero-Martin, PhD, Sitaram M. Emani, MD, Guillermo García-Cardeña, PhD, Pedro J. del Nido, MD, Ingeborg Friehs, MD
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2025-09-01
Цуврал:	JACC: Basic to Translational Science
Нөхцлүүд:	atorvastatin congenital heart disease endocardial fibroelastosis endothelial-mesenchymal transition hypoplastic left heart syndrome
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2452302X25001664
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!